10-Q: Moderna Q3 2025: Revenue Plunges, Key Pipeline Mixed

Moderna reported a significant revenue decline and net loss in Q3 2025, driven by lower COVID vaccine sales, while advancing its pipeline with new approvals and discontinuations.

Summary

• Net product sales for Q3 2025 decreased by 47% to $973 million, down from $1.82 billion in Q3 2024, primarily due to lower COVID vaccine sales.
• The company reported a net loss of $200 million, or $(0.51) per share, for Q3 2025, compared to a net income of $13 million, or $0.03 per share, in Q3 2024.
• For the nine months ended September 30, 2025, net product sales were $1.17 billion, a 46% decrease from $2.17 billion in the same period of 2024.
• The nine-month net loss improved to $1.996 billion, or $(5.15) per share, from a net loss of $2.441 billion, or $(6.37) per share, in the prior year.
• Moderna's new COVID vaccine, mNEXSPIKE, received FDA approval in May 2025 for adults aged 65 and older, and individuals 12-64 with risk factors, with commercial sales launched in Q3 2025.
• The RSV vaccine, mRESVIA, had its approved use expanded in June 2025 to include adults aged 18 through 59 years who are at increased risk for RSV disease.
• International mRNA manufacturing facilities in Australia and the United Kingdom became licensed and operational in Q3 2025, and the first mRNA vaccines fully manufactured in Canada were delivered in September 2025.
• The Phase 3 pivotal trial for the Cytomegalovirus (CMV) vaccine (mRNA-1647) did not meet its primary efficacy endpoint, leading to the discontinuation of the congenital CMV clinical development program.
• The Phase 1 study of the Glycogen storage disease type 1a (GSD1a) therapeutic (mRNA-3745) was discontinued to re-evaluate platform advancements.
• Moderna settled patent disputes with Alnylam Pharmaceuticals, Inc. on September 15, 2025, with no payments made by Moderna.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a substantial decline in Q3 revenue and a shift from net income to a significant net loss year-over-year. While there are positive pipeline advancements and manufacturing milestones, the financial performance for the quarter is a clear negative. The discontinuation of two clinical programs further dampens sentiment, despite an improvement in the nine-month net loss and cash used in operations.

Positives

• New COVID vaccine, mNEXSPIKE, received FDA approval in May 2025 and launched commercial sales in Q3 2025.
• Expanded approval for RSV vaccine, mRESVIA, in June 2025 to include adults 18-59 at increased risk in 31 countries.
• Positive preliminary immunogenicity data for 2025-2026 COVID vaccine formulas (Spikevax: >8-fold increase; mNEXSPIKE: >16-fold increase in antibodies).
• International mRNA manufacturing facilities in Australia and the UK became licensed and operational in Q3 2025, enhancing global supply capabilities.
• First mRNA vaccines fully manufactured in Canada delivered in September 2025, marking a significant manufacturing milestone.
• Progress in oncology pipeline with Phase 3 adjuvant melanoma fully enrolled and two NSCLC Phase 3 studies enrolling for intismeran autogene (mRNA-4157).
• Rare disease therapeutic for Propionic Acidemia (mRNA-3927) showed potential decreases in annualized metabolic decompensation event frequency and reached target enrollment for its registrational study.
• Methylmalonic Acidemia (MMA) therapeutic (mRNA-3705) selected by FDA for START pilot program, with pivotal study design agreed and registrational study expected in 2026.
• Net cash used in operating activities decreased by $1.0 billion, or 27%, for the nine months ended September 30, 2025, compared to the same period in 2024, indicating improved cash management.
• Settled patent infringement actions with Alnylam Pharmaceuticals, Inc. in Moderna's favor with no payments.

Negatives

• Net product sales for Q3 2025 decreased by 47% to $973 million from $1.82 billion in Q3 2024, primarily due to lower COVID vaccine sales.
• The company reported a net loss of $200 million for Q3 2025, a significant decline from a net income of $13 million in Q3 2024.
• Loss from operations for Q3 2025 worsened to $(260) million from $(70) million in Q3 2024.
• The Phase 3 pivotal trial for the Cytomegalovirus (CMV) vaccine (mRNA-1647) failed to meet its primary efficacy endpoint, leading to the discontinuation of the congenital CMV clinical development program.
• The Phase 1 study of the Glycogen storage disease type 1a (GSD1a) therapeutic (mRNA-3745) was discontinued.
• Cash and cash equivalents decreased by $795 million for the nine months ended September 30, 2025, resulting in a balance of $1.134 billion.
• Total cash, cash equivalents, and investments decreased by $2.9 billion, or 30%, from December 31, 2024, to September 30, 2025.
• Working capital decreased by $1.0 billion, or 17%, from December 31, 2024, to September 30, 2025.
• Anticipate a decline in net product sales for the full year 2025 compared to 2024 due to lower expected COVID vaccination rates and increased market competition.

Risks

• Ability to drive use of commercial products and increase market share, especially in evolving COVID and RSV vaccine markets.
• Impact of evolving markets on financial returns, particularly for commercial COVID and RSV vaccines.
• Ability to obtain and maintain regulatory approval for product candidates across the portfolio.
• Ability to successfully launch and commercialize products and the timing of launches.
• Ability of Moderna and third parties to successfully manufacture, supply, and distribute commercial products and future products at scale.
• Scope of protection for intellectual property rights and outcomes of pending legal proceedings related to intellectual property.
• Timing of initiation, progress, completion, results, and cost of clinical trials, preclinical studies, and R&D programs.
• Participant enrollment in clinical trials, including demographics and timing.
• Pricing and reimbursement of products, if approved.
• Estimates of future expenses, revenues, and capital requirements may prove wrong, leading to faster utilization of capital resources.
• Unforeseen expenses, difficulties, complications, delays, and other unknown factors in the development and commercialization of novel medicines.
• Decline in customer demand for COVID vaccine continuing into 2025 as the market transitions to a more competitive and commercially driven environment.
• Continued negative cash flows from operations in upcoming periods due to investment in future product launches.

Future Outlook

Moderna anticipates seasonal fluctuations in demand for its COVID and RSV vaccines, with higher sales expected during the fall and winter. The company expects a decline in net product sales for the full year 2025 compared to 2024, primarily due to lower expected COVID vaccination rates and a more competitive commercial market. While RSV vaccine sales are not expected to be a significant portion of total product sales in 2025, Moderna continues to invest in internal manufacturing capabilities for future product launches. The company forecasts continued negative cash flows from operations in upcoming periods due to significant investments in its pipeline, including oncology, norovirus, seasonal flu, and combination vaccine programs, as well as digital capabilities and global commercial infrastructure. Moderna believes its current financial resources, combined with expected product sales, will be sufficient to fund operations and capital expenditures for at least the next 12 months.

Management Comments

• "We anticipate seasonal fluctuations in demand for our COVID and RSV vaccines, with higher sales expected during the fall and winter seasons."
• "As COVID has transitioned to a seasonal respiratory vaccine, we anticipate a decline in net product sales for the full year 2025 compared to 2024, primarily due to lower expected vaccination rates and a more competitive commercial market environment."
• "Although we commenced sales of our RSV vaccine in the third quarter of 2024, product sales from our RSV vaccine are not expected to present a significant portion of total product sales in 2025."
• "We expect full year 2025 cost of sales to be lower compared to 2024, primarily driven by a reduction in period charges, particularly lower wind-down costs related to contract manufacturing organization contracts and inventory write-downs, along with lower anticipated sales volume."
• "We continue to anticipate a reduction in research and development expenses in 2025 compared to 2024, driven by disciplined cost management, portfolio prioritization, and a focused approach to pipeline execution."
• "We foresee that our commitment to investing in our business for future product launches may lead to continued negative cash flows from operations in upcoming periods."
• "We believe that our cash, cash equivalents, and investments as of September 30, 2025, together with cash expected to be generated from product sales, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months from the issuance of these financial statements included in this Form 10-Q."

Industry Context

Moderna operates in the highly competitive biotechnology and pharmaceutical industry, particularly in the mRNA vaccine and therapeutic space. The decline in COVID vaccine sales reflects a broader market shift as the pandemic transitions to an endemic phase, leading to lower vaccination rates and increased competition from other vaccine manufacturers. The expansion of Moderna's RSV vaccine approval positions it to compete in the growing respiratory virus vaccine market. The company's strategic investments in international manufacturing facilities align with a global trend towards localized production and pandemic preparedness. The mixed results in its pipeline, including the discontinuation of the congenital CMV program, highlight the inherent risks and high attrition rates in drug development, even for established platforms like mRNA. The focus on oncology and rare diseases indicates a diversification strategy beyond infectious diseases, targeting areas with high unmet medical needs and potentially higher margins.

Comparison to Industry Standards

• Moderna's significant decline in COVID vaccine sales reflects a broader industry trend where demand for initial pandemic-era vaccines has normalized. Competitors like Pfizer/BioNTech have also seen reduced COVID vaccine revenues, indicating a shift to a more competitive, seasonal market.
• The failure of the CMV vaccine (mRNA-1647) Phase 3 trial to meet its primary endpoint is a setback, but clinical trial failures are common in the pharmaceutical industry, with success rates for Phase 3 trials generally ranging from 50-60% across all therapeutic areas. This outcome is not unusual for a high-risk, high-reward development program.
• The expansion of mRESVIA's approval for younger at-risk adults positions Moderna to compete with other RSV vaccine developers, such as GSK (Arexvy) and Pfizer (Abrysvo), which have also secured approvals for older adults and, in some cases, maternal immunization. Moderna's expanded label could provide a competitive edge in certain demographics.
• Moderna's continued investment in its oncology pipeline, particularly personalized mRNA cancer vaccines (INT) in collaboration with Merck, aligns with a major industry focus on precision medicine and immunotherapy. This area is highly competitive, with numerous companies pursuing similar approaches, but also offers significant market potential.
• The establishment of international manufacturing facilities in Australia, the UK, and Canada demonstrates a strategic move towards decentralized manufacturing, a trend observed across the pharmaceutical industry to enhance supply chain resilience and meet local demand, especially in the wake of global health crises.

Legal Proceedings

• Moderna has brought patent-infringement actions against Pfizer Inc., BioNTech SE, and related entities in the U.S., Germany, the Netherlands, the UK, Ireland, and Belgium concerning its mRNA platform technology and vaccine designs.
• Pfizer and BioNTech have commenced actions or asserted defenses seeking to revoke Moderna's patents in these jurisdictions.
• Arbutus Biopharma Corporation and Genevant Sciences GmbH have brought patent-infringement actions against Moderna in the U.S. District Court for the District of Delaware, Canada, Japan, Switzerland, and the Unified Patent Court (UPC) asserting patents concerning lipid nanoparticles.
• GlaxoSmithKline Biologicals SA (GSK) has filed two complaints against Moderna in the U.S. District Court for the District of Delaware and two patent-infringement lawsuits in the UPC concerning liposomes and modified liposomes for RNA delivery.
• Northwestern University has filed a complaint against Moderna in the U.S. District Court for the District of Delaware asserting U.S. patents concerning lipid nanoparticle technology.
• Moderna is subject to shareholder class action and shareholder derivative litigation pending in the U.S. District Court for the District of Massachusetts related to statements about its RSV vaccine (mRNA-1345).

Stakeholder Impact

• **Shareholders:** Significant decline in Q3 revenue and net loss may negatively impact investor confidence and share price. Pipeline setbacks (CMV, GSD1a) add to development risk, while new approvals (mNEXSPIKE, mRESVIA expansion) and manufacturing milestones offer long-term potential. The settlement with Alnylam without payment is a positive for intellectual property risk.
• **Employees:** Discontinuation of clinical programs (CMV, GSD1a) could lead to internal resource reallocation or potential workforce adjustments. Continued investment in R&D and manufacturing facilities suggests ongoing opportunities in other areas.
• **Customers (Governments, Wholesalers, Healthcare Providers):** New COVID vaccine (mNEXSPIKE) and expanded RSV vaccine (mRESVIA) approvals provide more options. Localized manufacturing facilities in Australia, UK, and Canada enhance supply chain reliability and pandemic preparedness for respective governments.
• **Partners (Merck, Blackstone):** Collaboration with Merck on oncology therapeutics continues to advance. The funding arrangement with Blackstone for influenza vaccine development remains active, supporting that program.
• **Regulatory Authorities (FDA, EMA, Health Canada):** Continued engagement with regulatory bodies for approvals and guidance on pipeline candidates (e.g., seasonal flu, flu+COVID combination vaccine).

Next Steps

• Complete submissions for approval of seasonal flu vaccine (mRNA-1010) in the U.S., Canada, Australia, and Europe by January 2026.
• Refile seasonal flu + COVID combination vaccine (mRNA-1083) with Health Canada in 2025 and await further guidance from the FDA on refiling.
• Continue to evaluate CMV vaccine (mRNA-1647) in an ongoing Phase 2 trial of bone marrow transplant patients.
• Continue enrollment for two non-small cell lung cancer (NSCLC) Phase 3 studies, randomized Phase 2 studies for high-risk bladder cancer, and a Phase 2 study for first-line treatment of metastatic melanoma for intismeran autogene (mRNA-4157).
• Continue enrollment for Phase 2 portion of the checkpoint adaptive immune modulation therapy (AIM-T) study (mRNA-4359) in first-line metastatic melanoma and NSCLC.
• Start a registrational study for Methylmalonic Acidemia (MMA) therapeutic (mRNA-3705) in 2026.
• Assess the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-06) on consolidated financial statements and disclosures, with planned adoption of ASU 2023-09 in Q4 2025.

Key Dates

Recommendation

The filing presents a mixed picture. While Q3 2025 financial results show a significant year-over-year decline in revenue and a net loss, reflecting the challenging and competitive post-pandemic vaccine market, the nine-month net loss improved, and cash burn from operations decreased. The company has achieved important regulatory approvals for mNEXSPIKE and expanded mRESVIA, along with critical manufacturing milestones that strengthen its global footprint. However, the discontinuation of two clinical programs (CMV and GSD1a) highlights inherent R&D risks. The company's liquidity position is stated to be sufficient for the next 12 months, but continued negative operating cash flows are anticipated due to ongoing pipeline investments. Given the substantial revenue decline in the core COVID vaccine business, balanced by pipeline progress and strategic manufacturing, a 'hold' recommendation is appropriate. Investors should monitor the commercial uptake of mNEXSPIKE and mRESVIA, as well as further pipeline readouts, particularly for the seasonal flu and oncology programs, to assess future growth drivers.

Keywords

Moderna, mRNA, Vaccines, COVID-19, RSV, Oncology, Rare Disease, Biotechnology, Pharmaceuticals, Clinical Trials, Drug Development, SEC Filing, 10-Q, Financial Results, Pipeline, Spikevax, mRESVIA, mNEXSPIKE, Immunogenicity, Manufacturing, Patent Litigation